Novavax Stock Slips as B. Riley Trims Target but Keeps Buy Rating

Novavax finds itself caught between two narratives. On one side sits a beefed-up balance sheet and a fresh milestone check from Sanofi; on the other, a shrinking top line and a quarterly loss that refuses to budge. B. Riley Securities weighed both on Friday and came down cautiously optimistic, cutting its price target to $16 from $18 while leaving its buy rating in place.

The stock was down 2.9% on the day, a modest pullback that mirrors the analyst's own measured stance. The shares had already taken a harder knock earlier in the week, sliding 6.5% in the session following the earnings release.

A cash cushion, but at a cost

Novavax closed the third quarter of 2026 with $627 million in cash, cash equivalents, marketable securities and restricted cash as of September 30. That is a substantial war chest by any measure. Yet the same quarterly filing, submitted Thursday, showed a net loss of $31 million — a reminder that the company is still burning through its reserves rather than adding to them.

Revenue for the quarter came in at $68 million, down 3% year over year. The combination of a declining top line and a negative bottom line is what makes the investment case genuinely difficult: investors must decide how much credit to give the financial safety net versus how much weight to place on the underlying business trajectory.

Sanofi's check does a lot of the heavy lifting

The revenue picture looks rather different when viewed across the full year. Roughly two weeks ago, Novavax raised its 2026 adjusted revenue guidance to a range of $385 million to $415 million. Embedded in that forecast is a $125 million milestone payment earned in October, triggered when Sanofi launched a Phase 3 trial in Europe for a combined influenza-COVID-19 vaccine.

Should investors sell immediately? Or is it worth buying Novavax?

That payment is a concrete building block of the annual outlook — and a double-edged one. It validates the partnership and provides real cash. But it also raises a question analysts will keep circling: how much of the guidance depends on this single event, and how much rests on the rest of the business?

The bull case hinges on stabilization

For the more optimistic scenario to gain traction, Novavax needs to show that revenue is finding a floor. A steady top line, paired with a narrower loss, would give investors a business argument to set alongside the balance-sheet argument. The raised guidance provides a framework; hitting it while demonstrating a firmer underlying revenue base would strengthen the recovery thesis considerably.

B. Riley's decision to maintain its buy rating while trimming the target captures this tension precisely. The positive view survives, but within a tighter valuation range. Confidence, in other words, is warranted only to the extent that Novavax can actually deliver on its economic promises.

What could go wrong

The bear case writes itself from the current numbers. If the quarterly revenue decline persists and losses continue, skepticism about earnings power could outweigh the comfort of the cash pile. The composition of that $627 million matters too — it includes marketable securities and restricted cash, not just immediately available funds. Should losses continue, the trajectory of this financial position becomes a live concern.

There is also the milestone dependency to consider. Even if Novavax meets its annual guidance, the market may demand more than a target reached largely on the back of the Sanofi payment. A cheaper valuation, in the eyes of investors, would likely require evidence that the remaining revenue streams are stabilizing on their own.

The next real test

The coming months will be judged against one benchmark above all: whether Novavax delivers on its 2026 revenue range. How that revenue is composed will matter as much as the headline figure. A year that hits guidance while showing progress on both sales and earnings would support the recovery narrative; a continued slide alongside persistent losses would tilt the scales the other way.

For now, the stock sits at the intersection of financial security and operational uncertainty. The cash is real, the partnership is paying, and the analyst community has not walked away. But until the business itself shows it can stand on firmer ground, the balance sheet will remain the main pillar holding up the investment case.

Ad

Novavax Stock: New Analysis - 11 November

Fresh Novavax information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novavax analysis...